#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Von Willebrand's disease Diffuse large B-cell lymphoma Arrhythmia Vulval cancer Activated PI3 kinase delta syndrome Erythema Renal transplant Familial amyotrophic lateral sclerosis Small cell lung cancer limited stage Osteomyelitis Hyperinsulinism Plasma cell myeloma refractory Oesophageal squamous cell carcinoma stage III Hyperchylomicronaemia Homocystinuria More trials…

    Learn about Rare Diseases

    Rett syndrome – Treatment Hereditary angioedema with C1 esterase inhibitor deficiency – Diagnostics Nodal marginal zone B-cell lymphoma – Diagnostics Rhabdoid tumour – Life with Disease Turner’s syndrome – Treatment Hyperoxaluria MELAS syndrome – Basic Information Aicardi-Goutieres syndrome – Treatment Familial haemophagocytic lymphohistiocytosis – Life with Disease Primary hyperoxaluria – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bleomycin Sulfate Ph. Eur. Pf-06480605 Sucrose Tenofovir Disoproxil Fumarate Vixarelimab S-241656 Prucalopride Timbetasin Acetate Human Cancellous Bone Lisaftoclax Efmoroctocog Alfa Nebivolol Hydrochloride [89Zr]Bms-986279 Potassium Oxybate Exagamglogene Autotemcel Pristinamycin Vincristine Oric-114 Regn7075 Crovalimab More therapies…

    Learn about Your Condition

    Bartonellosis Myocardial infarction Hand fracture Metastases to biliary tract Desmoplastic melanoma Muscle strain Vesicoureteric reflux Sickle cell anaemia Acute hepatic failure Acne Progressive supranuclear palsy Ovarian cancer metastatic Frostbite Encephalitis Japanese B Anal fissure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Specderm Poznanska Sp. j.

Specderm Poznanska Sp. j.

Ul. Prezydenta Ryszarda Kaczorowskiego 7/u 50, Bialystok, 15-375, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of LY3454738 for Treating Moderate-to-Severe Atopic Dermatitis in Adults

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Ly3454738
    • Other Emollients And Protectives
    • Sodium Chloride Solution 0.9%
    Hungary Italy Poland

  • Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Dapagliflozin Propanediol
    • Metformin Embonate
    Bulgaria Croatia Germany Greece Hungary Poland +3

  • Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-77242113
    • Ustekinumab
    Austria Belgium Denmark Germany Hungary Poland +2

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Drugs:
    • Envudeucitinib
    Austria Belgium Bulgaria Czechia Estonia France +7

  • Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Jnj-77242113
    • Ustekinumab
    Bulgaria Czechia Denmark Germany Hungary Poland +1

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    • Apremilast
    Austria Estonia France Germany Hungary Latvia +3

  • Study on the Effectiveness and Safety of 0.1% Mometasone Furoate Emulsion and Ecural Cream for Adults with Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Mometasone Furoate Ph. Eur.
    • Mometasone Furoate
    Poland

  • Study of N-Acetyl-GED-0507-34-LEVO 5% gel applied daily for 12 weeks in patients with acne vulgaris

    Not recruiting

    3 1
    Investigated Drugs:
    • (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
    Italy Poland Spain

  • Title: Long-term safety study of N-Acetyl-GED-0507-34-LEVO gel 5% applied to the skin for patients with acne vulgaris

    Not recruiting

    3 1 1
    Investigated Drugs:
    • (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
    Italy Poland Spain

  • Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Metformin
    • Dapagliflozin
    Germany Poland
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!